The effects of O⁶-methyl guanine DNA-methyl transferase promotor methylation and CpG1, CpG2, CpG3 and CpG4 methylation on treatment response and their prognostic significance in patients with glioblastoma

1Shaw EG, Debinski W, Robbins ME. Central nervous system tumors. In: Gunderson LL, Tepper JE, Editors. Clinical Radiation Oncology, 2nd ed. Philadelphia, PA, USA: Elsevier Churchill Livingstone; 2007:457-493.ShawEGDebinskiWRobbinsMECentral nervous system tumorsGundersonLLTepperJEEditorsClinical Radiation Oncology, 2nd edPhiladelphia, PA, USAElsevier Churchill Livingstone2007457493Search in Google Scholar

2Siker ML, Donahue BR, Vogelbaum MA, Tome WA, Gilbert ML, Mehta MP. Primer intracranial neoplasms. In: Halperin EC, Perez CA, Brady LW, Editors. Principles and Practice of Radiation Oncology, 5th ed. Philadelphia, PA, USA: Wolters-Lippincott; 2008: 717-751.SikerMLDonahueBRVogelbaumMATomeWAGilbertMLMehtaMPPrimer intracranial neoplasmsHalperinECPerezCABradyLWEditorsPrinciples and Practice of Radiation Oncology, 5th edPhiladelphia, PA, USAWolters-Lippincott2008717751Search in Google Scholar

3Stieber VW, McMullen KP, Munley MT, Shaw EG. Central nervous system tumors. In: Levitt SH, Purdy JA, Perez CA, Vijayakumar S, Editors. Technical Basis of Radiation Therapy, 4th ed. Berlin, Germany: Springer; 2006: 425-453.StieberVWMcMullenKPMunleyMTShawEGCentral nervous system tumorsLevittSHPurdyJAPerezCAVijayakumarSEditorsTechnical Basis of Radiation Therapy, 4th edBerlin, GermanySpringer200642545310.1007/3-540-35665-7_17Search in Google Scholar

4Donahue BR. Adult gliomas. In: Lu JJ, Brady LW, Editors. Radiation Oncology - An Evidence-Based Approach, 1st ed. Berlin, Germany: Springer; 2008: 483-501.DonahueBRAdult gliomasLuJJBradyLWEditorsRadiation Oncology - An Evidence-Based Approach, 1st edBerlin, GermanySpringer200848350110.1007/978-3-540-77385-6_33Search in Google Scholar

5Woo SY. Central nervous system. In: Cox JD, Ang KK, Editors. Radiation Oncology. Philadelphia, PA, USA: Mosby Elsevier; 2010: 835-875.WooSYCentral nervous systemCoxJDAngKKEditorsRadiation OncologyPhiladelphia, PA, USAMosby Elsevier2010835875Search in Google Scholar

6Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(7): 277-300.JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin2010;60727730010.3322/caac.20073Search in Google Scholar

7Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoom MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352(10): 987-996.StuppRMasonWPvan den BentMJWellerMFisherBTaphoomMJet alRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053521098799610.1056/NEJMoa043330Search in Google Scholar

8Weiler M, Hartmann C, Wiewrodt D, Herrlinger U, Gorlia T, Bähr O, et al. Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol Phys. 2010; 77(3): 670-676.WeilerMHartmannCWiewrodtDHerrlingerUGorliaTBährOet alChemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomideInt J Radiat Oncol Biol Phys201077367067610.1016/j.ijrobp.2009.05.031Search in Google Scholar

9Trivedi RN, Almeida KH, Fomsaglio JL, Schamus S, Sobol RW. The role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell death. Cancer Res. 2005; 65(14): 6394-6400.TrivediRNAlmeidaKHFomsaglioJLSchamusSSobolRWThe role of base excision repair in the sensitivity and resistance to temozolomide-mediated cell deathCancer Res200565146394640010.1158/0008-5472.CAN-05-0715Search in Google Scholar

10Pegg AE, Dolan ME, Moschel RC. Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995; 51: 167-223.PeggAEDolanMEMoschelRCStructure, function, and inhibition of O6-alkylguanine-DNA alkyltransferaseProg Nucleic Acid Res Mol Biol19955116722310.1016/S0079-6603(08)60879-XSearch in Google Scholar

11Gerson SL. Clinical relevance of MGMT in the treatment of cancer.J Clin Oncol 2002;20:2388-99.GersonSLClinical relevance of MGMT in the treatment of cancerJ Clin Oncol20022023889910.1200/JCO.2002.06.11011981013Search in Google Scholar

12Gerson SL, Trey JE, Miller K, Berger NA. Comparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 1986; 7(5): 745-49.GersonSLTreyJEMillerKBergerNAComparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissuesCarcinogenesis1986757454910.1093/carcin/7.5.7453698202Search in Google Scholar

13Dumenco LL, Allay E, Norton K, Gerson SL. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science. 1993; 259(5092): 219-222.DumencoLLAllayENortonKGersonSLThe prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferaseScience1993259509221922210.1126/science.84217828421782Search in Google Scholar

14Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyl-transferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol. 2008; 26(25): 4189-4199.HegiMELiuLHermanJGStuppRWickWWellerMet alCorrelation of O6-methylguanine methyl-transferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activityJ Clin Oncol200826254189419910.1200/JCO.2007.11.596418757334Search in Google Scholar

15Watts GS, Pieper RO, Costello JF, Peng YM, Dalton WS, Futscher BW. Methylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997; 17(9): 5612-5619.WattsGSPieperROCostelloJFPengYMDaltonWSFutscherBWMethylation of discrete regions of the O6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the geneMol Cell Biol19971795612561910.1128/MCB.17.9.56122324099271436Search in Google Scholar

16Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005; 352(10): 997-1003.HegiMEDiserensACGorliaTHamouMFde TriboletNWellerMet alMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med200535210997100310.1056/NEJMoa04333115758010Search in Google Scholar

17Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer. 2009; 101(1): 124-131.DunnJBaborieAAlamFJoyceKMoxhamMSibsonRet alExtent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapyBr J Cancer2009101112413110.1038/sj.bjc.6605127271369719536096Search in Google Scholar

18Cao VT, Jung TY, Jung S, Jin SG, Moon KS, Kim IY, et al. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glio-blastomas. Neurosurgery. 2009; 65(5): 866-875; discussion: 875.CaoVTJungTYJungSJinSGMoonKSKimIYet alThe correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glio-blastomasNeurosurgery2009655866875discussion: 87510.1227/01.NEU.0000357325.90347.A119834398Search in Google Scholar

19Tang K, Jin Q, Yan W, Zhang W, You G, Liu Y, et al. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Med Oncol. 2012; 29(2): 1292-1296.TangKJinQYanWZhangWYouGLiuYet alClinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patientsMed Oncol20122921292129610.1007/s12032-011-9901-421394635Search in Google Scholar

20Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000; 343(19): 1350-1354.EstellerMGarcia-FoncillasJAndionEGoodmanSNHidalgoOFVanaclochaVet alInactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agentsN Engl J Med2000343191350135410.1056/NEJM20001109343190111070098Search in Google Scholar

21Paz MF, Yaya-Tur R, Rojas-Marcos I, Reynes G, Pollan M, Aguirre-Cruz L, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res. 2004; 10(15): 4933-4938.PazMFYaya-TurRRojas-MarcosIReynesGPollanMAguirre-CruzLet alCpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomasClin Cancer Res200410154933493810.1158/1078-0432.CCR-04-039215297393Search in Google Scholar

22Shah N, Lin B, Sibenaller Z, Ryken T, Lee H, Yoon JG, et al. Comprehensive analysis of MGMT promoter methylation: Correlation with MGMT expression and clinical response in GBM. PLoS One. 2011; 6(1): el6146.ShahNLinBSibenallerZRykenTLeeHYoonJGet alComprehensive analysis of MGMT promoter methylation: Correlation with MGMT expression and clinical response in GBMPLoS One201161el614610.1371/journal.pone.0016146301754921249131Search in Google Scholar

23Binabaj MM, Bahrami A, ShahidSales S, Joodi M, Mashhad MJ, Hassanian SM, et al.. The prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trials. Cell Physiol. 2018; 233(1): 378-386.BinabajMMBahramiAShahidSalesSJoodiMMashhadMJHassanianSMet alThe prognostic value of MGMT promoter methylation in glioblastoma: A meta-analysis of clinical trialsCell Physiol2018233137838610.1002/jcp.2589628266716Search in Google Scholar

24Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, et al. Prognostic value of 06-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods. JNeurooncol. 2010; 97(3): 311-322.Karayan-TaponLQuillienVGuilhotJWagerMFromontGSaikaliSet alPrognostic value of 06-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methodsJNeurooncol201097331132210.1007/s11060-009-0031-119841865Search in Google Scholar